International Clinical Trial: Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07733856) titled 'Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)' on July 23.

Study Type: Expanded Access

Primary Sponsor: Spruce Biosciences

Condition: Mucopolysaccharidosis Type IIIB MPS IIIB (Sanfilippo B Syndrome)

Intervention: Drug: Tralesinidase alfa (TA)

Recruitment Status: Not recruiting

Date of First Enrollment: July 31, 2026

To know more, visit https://clinicaltrials.gov/study/NCT07733856

Disclaimer: Curated by HT Syndication....